{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:58:52Z","timestamp":1793123932134,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.bmc.2023.117577","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T23:04:22Z","timestamp":1704409462000},"page":"117577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Exploiting high-energy hydration sites for the discovery of potent peptide aldehyde inhibitors of the SARS-CoV-2 main protease with cellular antiviral activity"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2741-8899","authenticated-orcid":false,"given":"Daniel W.","family":"Carney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abba E.","family":"Leffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asela S.","family":"Chandrasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9534-0291","authenticated-orcid":false,"given":"Edcon","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Dornford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Dougan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah L.","family":"Frye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3891-3714","authenticated-orcid":false,"given":"Mary E.","family":"Grimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Knehans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9113-0921","authenticated-orcid":false,"given":"Jennifer L.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallareddy","family":"Komandla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8338-3788","authenticated-orcid":false,"given":"Weston","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia R.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Phimister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar S.","family":"Saikatendu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hercules","family":"Silverstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaghayegh","family":"Vafaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2023.117577_b0005","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2023.117577_b0010","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2023.117577_b0015","unstructured":"WHO COVID-19 dashboard. https:\/\/covid19.who.int\/(accessed 01\/12\/2024)."},{"key":"10.1016\/j.bmc.2023.117577_b0020","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.bmc.2023.117577_b0025","unstructured":"Boras B, Jones RM, Anson BJ, et al. Discovery of a novel inhibitor of coronavirus 3CL protease for the potential treatment of COVID-19. bioRxiv 2021, 2020.09.12.293498."},{"key":"10.1016\/j.bmc.2023.117577_b0030","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.abf1611","article-title":"SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model","volume":"371","author":"Qiao","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.bmc.2023.117577_b0035","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1021\/acs.jmedchem.1c00598","article-title":"Structure-based optimization of ML300-derived, noncovalent inhibitors targeting the severe acute respiratory syndrome coronavirus 3CL protease (SARS-CoV-2 3CLpro)","volume":"65","author":"Han","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117577_b0040","unstructured":"US FDA. Paxlovid emergency use authorization; 2022."},{"key":"10.1016\/j.bmc.2023.117577_b0045","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3390\/biom11040607","article-title":"SARS-CoV-2 Mpro: a potential target for peptidomimetics and small-molecule inhibitors","volume":"11","author":"Citarella","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.bmc.2023.117577_b0050","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3390\/biom13091339","article-title":"Recent advances in SARS-CoV-2 main protease inhibitors: from nirmatrelvir to future perspectives","volume":"13","author":"Citarella","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.bmc.2023.117577_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115772","article-title":"Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: a comprehensive review","volume":"260","author":"Li","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2023.117577_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijbiomac.2021.02.071","article-title":"Potential drug targets of SARS-CoV-2: from genomics to therapeutics","volume":"177","author":"Shamsi","year":"2021","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.bmc.2023.117577_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127377","article-title":"The SARS-CoV-2 main protease as drug target","volume":"30","author":"Ullrich","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2023.117577_b0070","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.bmc.2023.117577_b0075","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2023.117577_b0080","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.drudis.2020.12.005","article-title":"Potential SARS-CoV-2 main protease inhibitors","volume":"26","author":"Banerjee","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmc.2023.117577_b0085","article-title":"Design of wide-spectrum inhibitors targeting coronavirus main proteases","volume":"3","author":"Yang","year":"2005","journal-title":"PLoS Biol"},{"key":"10.1016\/j.bmc.2023.117577_b0090","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1021\/jm0603926","article-title":"Synthesis, crystal structure, structure\u2212activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor","volume":"49","author":"Yang","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117577_b0095","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.antiviral.2011.08.001","article-title":"Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease","volume":"92","author":"Zhu","year":"2011","journal-title":"Antivir Res"},{"key":"10.1016\/j.bmc.2023.117577_b0100","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/cbic.200500533","article-title":"An efficient method for the synthesis of peptide aldehyde libraries employed in the discovery of reversible SARS coronavirus main protease (SARS-CoV Mpro) inhibitors","volume":"7","author":"Al-Gharabli","year":"2006","journal-title":"Chembiochem"},{"key":"10.1016\/j.bmc.2023.117577_b0105","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.bmc.2023.117577_b0110","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bmc.2023.117577_b0115","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1038\/s41467-020-18233-x","article-title":"Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease","volume":"11","author":"Fu","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2023.117577_b0120","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1073\/pnas.0610202104","article-title":"Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding","volume":"104","author":"Young","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2023.117577_b0125","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1021\/ja512751q","article-title":"Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field","volume":"137","author":"Wang","year":"2015","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2023.117577_b0130","doi-asserted-by":"crossref","first-page":"12197","DOI":"10.1038\/s41598-022-15930-z","article-title":"Hepatitis C virus NS3\/4A inhibitors and other drug-like compounds as covalent binders of SARS-CoV-2 main protease","volume":"12","author":"Andi","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2023.117577_b0135","unstructured":"LiveDesign Version 8.11.1. New York, NY: Schr\u00f6dinger, Inc."},{"key":"10.1016\/j.bmc.2023.117577_b0140","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00840-23","article-title":"Evaluation of in vitro antiviral activity of SARS-CoV-2 Mpro inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions","volume":"67","author":"Tong","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2023.117577_b0145","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117577_b0150","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1038\/s41467-021-26239-2","article-title":"Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19","volume":"12","author":"Boras","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2023.117577_b0155","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s10822-020-00341-x","article-title":"An online repository of solvation thermodynamic and structural maps of SARS-CoV-2 targets","volume":"34","author":"Olson","year":"2020","journal-title":"J Comput-Aided Mol Des"},{"key":"10.1016\/j.bmc.2023.117577_b0160","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/pro.177","article-title":"High-energy water sites determine peptide binding affinity and specificity of PDZ domains","volume":"18","author":"Beuming","year":"2009","journal-title":"Protein Sci"},{"key":"10.1016\/j.bmc.2023.117577_b0165","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.2174\/1568026617666170414141452","article-title":"Calculating water thermodynamics in the binding site of proteins - applications of WaterMap to drug discovery","volume":"17","author":"Cappel","year":"2017","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmc.2023.117577_b0170","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/03602532.2018.1555587","article-title":"Aldehyde toxicity and metabolism: the role of aldehyde dehydrogenases in detoxification, drug resistance and carcinogenesis","volume":"51","author":"Ahmed Laskar","year":"2019","journal-title":"Drug Metabolism Rev"},{"key":"10.1016\/j.bmc.2023.117577_b0175","unstructured":"Ghosh AK, Yadav M, Mesecar A. Preparation of bis-amide peptidomimetics for the treatment of SARS. WO2022251615; 2022."},{"key":"10.1016\/j.bmc.2023.117577_b0180","unstructured":"Oruganti S, Eda VVVR, Shinde MM, et al. Improved preparation of nirmatrelvir and intermediates using continuous flow processes. WO2023148747; 2023."},{"key":"10.1016\/j.bmc.2023.117577_b0185","series-title":"Methods Enzymol.","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","article-title":"[20] Processing of X-ray diffraction data collected in oscillation mode","author":"Otwinowski","year":"1997"},{"key":"10.1016\/j.bmc.2023.117577_b0190","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1107\/S0021889897006766","article-title":"MOLREP: an automated program for molecular replacement","volume":"30","author":"Vagin","year":"1997","journal-title":"J Appl Crystallogr"},{"key":"10.1016\/j.bmc.2023.117577_b0195","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J Appl Crystallogr"},{"key":"10.1016\/j.bmc.2023.117577_b0200","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1107\/S0907444996012255","article-title":"Refinement of macromolecular structures by the maximum-likelihood method","volume":"53","author":"Murshudov","year":"1997","journal-title":"Acta Crystallogr Sect D: Biol Crystallogr"},{"key":"10.1016\/j.bmc.2023.117577_b0205","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr Sect D: Biol Crystallogr"},{"key":"10.1016\/j.bmc.2023.117577_b0210","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1107\/S0907444911007773","article-title":"Data processing and analysis with the autoPROC toolbox","volume":"67","author":"Vonrhein","year":"2011","journal-title":"Acta Crystallogr D"},{"key":"10.1016\/j.bmc.2023.117577_b0215","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1107\/S0907444913000061","article-title":"How good are my data and what is the resolution?","volume":"69","author":"Evans","year":"2013","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.bmc.2023.117577_b0220","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1107\/S0907444912017453","article-title":"Significant reduction in errors associated with nonbonded contacts in protein crystal structures: automated all-atom refinement with PrimeX","volume":"68","author":"Bell","year":"2012","journal-title":"Acta Crystallogr Sect D: Biol Crystallogr"},{"key":"10.1016\/j.bmc.2023.117577_b0225","series-title":"International tables for crystallography, set, volumes A - G, OnlineMRW","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1107\/97809553602060000864","article-title":"PrimeX and the Schr\u00f6dinger computational chemistry suite of programs","author":"Bell","year":"2012"},{"key":"10.1016\/j.bmc.2023.117577_b0230","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/toxins13030193","article-title":"Potency-enhancing mutations of gating modifier toxins for the voltage-gated sodium channel NaV1.7 can be predicted using accurate free-energy calculations","volume":"13","author":"Katz","year":"2021","journal-title":"Toxins"},{"key":"10.1016\/j.bmc.2023.117577_b0235","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1021\/acs.jcim.2c00072","article-title":"AutoDesigner, a De Novo design algorithm for rapidly exploring large chemical space for lead optimization: application to the design and synthesis of d-amino acid oxidase inhibitors","volume":"62","author":"Bos","year":"2022","journal-title":"J Chem Inf Model"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962300425X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962300425X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T20:19:23Z","timestamp":1714767563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096808962300425X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":47,"alternative-id":["S096808962300425X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117577","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploiting high-energy hydration sites for the discovery of potent peptide aldehyde inhibitors of the SARS-CoV-2 main protease with cellular antiviral activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117577","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117577"}}